---
title: "CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265800829.md"
datetime: "2025-11-13T22:23:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265800829.md)
  - [en](https://longbridge.com/en/news/265800829.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265800829.md)
generator: "portal-rs"
---

# CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -1.35.

### Segment Revenue

-   **Research and Development Expenses**: $2,848,544 for the three months ended September 30, 2025, compared to $1,428,504 for the same period in 2024, representing a 99.5% increase.
-   **General and Administrative Expenses**: $3,147,291 for the three months ended September 30, 2025, compared to $1,853,583 for the same period in 2024, representing a 69.7% increase.

### Operational Metrics

-   **Net Loss**: $7,341,062 for the three months ended September 30, 2025, compared to $4,125,643 for the same period in 2024, representing a 77.9% increase.
-   **Operating Loss**: $5,995,835 for the three months ended September 30, 2025, compared to $3,282,087 for the same period in 2024, representing an 82.7% increase.

### Cash Flow

-   **Net Cash Used in Operating Activities**: $13,647,893 for the nine months ended September 30, 2025, compared to $14,371,857 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $7,561,207 for the nine months ended September 30, 2025, compared to $24,372,928 for the same period in 2024.

### Unique Metrics

-   **Issuance Cost and Change in Fair Value of Derivative**: $772,169 for the three months ended September 30, 2025, compared to $894,039 for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to seek regulatory approval for CTx-1301 and continue research and development activities for existing and new product candidates, primarily CTx-1301.
-   **Non-Core Business**: The company is evaluating additional therapeutic areas where its PTR technology may be employed to develop future product candidates.
-   **Priority**: The company believes it will need to raise approximately $9 million of additional capital to advance its commercialization efforts for CTx-1301 through its PDUFA date of May 31, 2026.

### Related Stocks

- [CINGW.US](https://longbridge.com/en/quote/CINGW.US.md)

## Related News & Research

- [Why is your gold waiting on a speech?](https://longbridge.com/en/news/296733808.md)
- [North Sea Crude-WTI weakens on lower offer](https://longbridge.com/en/news/296813963.md)
- [Nvidia Earnings: Wall Street Expects Growth to Slow in Q2 — Dan Niles Says Hyperscalers Are Spending Like Never Before](https://longbridge.com/en/news/296822352.md)
- [There’s More to Consider, Says Investor About Sandisk Stock](https://longbridge.com/en/news/296795615.md)
- [AMD or Nvidia: Load Up on One AI Chip Stock, but Avoid the Other, Says Investor](https://longbridge.com/en/news/296792383.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**